Tempest Therapeutics, Inc. Cost of Revenue
Tempest Therapeutics, Inc. (TPST) reported Cost of Revenue of $44.00 thousand for the 3-month period ending 2018-09-30, per its 10-Q filed 2018-11-09.
Discontinued › Expense Statement
us-gaap:CostOfRevenue · last filed 2018-11-09
- Tempest Therapeutics, Inc. cost of revenue for the quarter ending 2018-09-30 was $44.00K, a 51.72% increase year-over-year.
- Tempest Therapeutics, Inc. cost of revenue for the quarter ending 2018-06-30 was $54.00K, a 80.29% decline year-over-year.
- Tempest Therapeutics, Inc. cost of revenue for the quarter ending 2018-03-31 was $112.00K, a 58.36% decline year-over-year.
- Tempest Therapeutics, Inc. cost of revenue for the quarter ending 2017-12-31 was $218.00K, a 84.79% decline year-over-year.
- Tempest Therapeutics, Inc. cost of revenue for fiscal 2017 was $790.00K, a 85.37% decline from fiscal 2016.
- Tempest Therapeutics, Inc. cost of revenue for fiscal 2016 was $5.40M, a 140.15% increase from fiscal 2015.
- Tempest Therapeutics, Inc. cost of revenue for fiscal 2015 was $2.25M.
- Tempest Therapeutics, Inc. cost of revenue for fiscal 2014 was $0.00.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2018-09-30 | $44.00K 10-Q · filed 2018-11-09 | $98.00K derived: sum of 2 quarters · filed 2018-11-09 | $210.00K 10-Q · filed 2018-11-09 | $428.00K derived: sum of 4 quarters · filed 2018-11-09 |
| 2018-06-30 | $54.00K 10-Q · filed 2018-08-09 | $166.00K 10-Q · filed 2018-08-09 | $384.00K derived: sum of 3 quarters · filed 2018-08-09 | $413.00K derived: sum of 4 quarters · filed 2018-11-09 |
| 2018-03-31 | $112.00K 10-Q · filed 2018-05-03 | $330.00K derived: sum of 2 quarters · filed 2018-05-03 | $359.00K derived: sum of 3 quarters · filed 2018-11-09 | $633.00K derived: sum of 4 quarters · filed 2018-11-09 |
| 2017-12-31 | $218.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $247.00K derived: sum of 2 quarters · filed 2018-11-09 | $521.00K derived: sum of 3 quarters · filed 2018-11-09 | $790.00K 10-K · filed 2018-03-15 |
| 2017-09-30 | $29.00K 10-Q · filed 2018-11-09 | $303.00K derived: sum of 2 quarters · filed 2018-11-09 | $572.00K 10-Q · filed 2018-11-09 | $2.00M derived: sum of 4 quarters · filed 2018-11-09 |
| 2017-06-30 | $274.00K 10-Q · filed 2018-08-09 | $543.00K 10-Q · filed 2018-08-09 | $1.98M derived: sum of 3 quarters · filed 2018-08-09 | $3.54M derived: sum of 4 quarters · filed 2018-08-09 |
| 2017-03-31 | $269.00K 10-Q · filed 2018-05-03 | $1.70M derived: sum of 2 quarters · filed 2018-05-03 | $3.26M derived: sum of 3 quarters · filed 2018-05-03 | $4.49M derived: sum of 4 quarters · filed 2018-05-03 |
| 2016-12-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $2.99M derived: sum of 2 quarters · filed 2018-03-15 | $4.22M derived: sum of 3 quarters · filed 2018-03-15 | $5.40M 10-K · filed 2018-03-15 |
| 2016-09-30 | $1.56M 10-Q · filed 2017-11-02 | $2.79M derived: sum of 2 quarters · filed 2017-11-02 | $3.97M 10-Q · filed 2017-11-02 | $5.13M derived: sum of 4 quarters · filed 2018-03-15 |
| 2016-06-30 | $1.23M 10-Q · filed 2017-08-03 | $2.41M 10-Q · filed 2017-08-03 | $3.57M derived: sum of 3 quarters · filed 2018-03-15 | $4.51M derived: sum of 4 quarters · filed 2018-03-15 |
| 2016-03-31 | $1.18M 10-Q · filed 2017-05-09 | $2.33M derived: sum of 2 quarters · filed 2018-03-15 | $3.27M derived: sum of 3 quarters · filed 2018-03-15 | $3.39M derived: sum of 4 quarters · filed 2018-03-15 |
| 2015-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $2.10M derived: sum of 2 quarters · filed 2018-03-15 | $2.21M derived: sum of 3 quarters · filed 2018-03-15 | $2.25M 10-K · filed 2018-03-15 |
| 2015-09-30 | $940.00K 10-Q · filed 2016-11-03 | $1.06M derived: sum of 2 quarters · filed 2016-11-03 | $1.09M 10-Q · filed 2016-11-03 | $1.09M derived: sum of 4 quarters · filed 2017-03-02 |
| 2015-06-30 | $116.00K 10-Q · filed 2016-08-04 | $151.00K 10-Q · filed 2016-08-04 | $151.00K derived: sum of 3 quarters · filed 2017-03-02 | $151.00K derived: sum of 4 quarters · filed 2017-03-02 |
| 2015-03-31 | $35.00K 10-Q · filed 2016-05-05 | $35.00K derived: sum of 2 quarters · filed 2017-03-02 | $35.00K derived: sum of 3 quarters · filed 2017-03-02 | $35.00K derived: sum of 4 quarters · filed 2017-03-02 |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-02 | $0.00 derived: sum of 2 quarters · filed 2017-03-02 | $0.00 derived: sum of 3 quarters · filed 2017-03-02 | $0.00 10-K · filed 2017-03-02 |
| 2014-09-30 | $0.00 10-Q · filed 2015-11-05 | $0.00 derived: sum of 2 quarters · filed 2015-11-05 | $0.00 10-Q · filed 2015-11-05 | |
| 2014-06-30 | $0.00 10-Q · filed 2015-08-10 | $0.00 10-Q · filed 2015-08-10 | ||
| 2013-12-31 | $0.00 10-K · filed 2016-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |